Only in Titles

           Search results for: Digestive system disease tissue array, 38 cases 38 cores   

paperclip

#24805857   2014/06/12 Save this To Up

SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Prognostic biomarkers that stratify patients with cancer are needed. Recent studies from Asia have implicated SALL4, a stem cell marker, as useful in identifying aggressive cases of hepatocellular carcinoma (HCC), and >50% of the cases tested had upregulation by microarray or dense immunoreactivity. Given the differences in predominant etiologic factors between the Asian and Western HCC, we sought to determine the prevalence of SALL4 immunoreactivity and its clinical relevance in Western HCC patients. We constructed tissue microarrays from 236 adult HCCs. Two cores each of tumor and nontumor tissue were included for each case. SALL4 immunohistochemistry was scored in a semiquantitative manner and the results correlated with recurrence-free and overall survival, in addition to standard demographics. Among the 236 cases, 165 (70.0%) were male. The median age was 59 years (range: 19 to 83 y). The majority (78.4%) of patients were white, followed by African American (15.7%), Asian (3.8%), Hispanic (1.7%), and Native American (0.4%). The majority of patients had hepatitis C (42.8%), followed by alcoholic liver disease and hepatitis B (both 8.9%), and nonalcoholic steatohepatitis (3.8%). SALL4 immunoreactivity was detected in a total of 3 cases (1.3%), and nonreactivity was validated on tissue sections from 73 cases. By univariate analysis, the SALL4-positive cases had significantly higher tumor grade (P=0.0251), more frequent lymphovascular invasion (P=0.0150), and shorter recurrence-free survival (7.90 vs. 57.54 mo; P=0.0115) and overall survival (7.90 vs. 64.87 mo; P=0.0018). Although SALL4 immunoreactivity in Western HCC is correlated with higher grade and poor prognosis, this is a rare event. Therefore, universal application of SALL4 as a biomarker for HCC should be performed with caution.

1802 related Products with: SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Liver hepatocellular carc Hepatocellular carcinoma Hepatocellular carcinoma Hepatocellular carcinoma Hepatocellular carcinoma Normal liver and hepatoce Multi organ carcinoma tis Multi organ carcinoma tis Pancreatic carcinoma and Liver carcinoma and norma Liver carcinoma and norma Liver carcinoma and norma

Related Pathways

paperclip

#17318972   2007/02/23 Save this To Up

Chromogenic in situ hybridization analysis of chromosomes 7, 9, and 17 in pancreatic ductal adenocarcinoma based on tissue microarrays.

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive neoplasm. Many different chromosomal alterations have been identified including structural or numerical changes. In this study we performed a molecular analysis of chromosomes 7,9, and 17 based on tissue microarrays (TMA).

2463 related Products with: Chromogenic in situ hybridization analysis of chromosomes 7, 9, and 17 in pancreatic ductal adenocarcinoma based on tissue microarrays.

Pancreatic duct adenocarc Top five cancer tissue ar Pancreatic carcinoma and Stomach adenocarcinoma wi Lung adenocarcinoma and n Lung adenocarcinoma tissu Colon adenocarcinoma (com Breast invasive ductal ca Ovary serous papillary ad Colon normal tissue array Breast invasive ductal ca High density breast invas

Related Pathways

paperclip

#15043305   2004/03/26 Save this To Up

CD44 loss in gastric stromal tumors as a prognostic marker.

The adhesion molecule CD44 (CD44s; CD44H) and its isoforms (CD44v3-6 and v9) are preferentially expressed by different cell types. These transmembrane glycoproteins are involved in cell-cell and cell-matrix interactions and in cell trafficking and, thus, may play a role in tumor metastasis and/or local invasion. The expression pattern of CD44s and variant isoforms, particularly CD44v6 and CD44v9, of some neoplasms, including soft tissue tumors, correlates with clinical course and outcome. The clinical behavior of gastrointestinal stromal tumors (GIST) is site specific; however, other reliable predictors of clinical outcome have not been identified. Thus, the prognostic value of CD44s and isoform expression in GIST were evaluated by immunohistochemistry of tissue microarrays.

2143 related Products with: CD44 loss in gastric stromal tumors as a prognostic marker.

EMAP-II Inhibitor Z-ASTD- EMAP-II Inhibitor Z-ASTD- EMAP II Inhibitor Z ASTD EMAP II Inhibitor Z ASTD Amplite™ Fluorimetric H Amplite™ Intracellular Amplite™ Fluorimetric P Amplite™ Fluorimetric A Cell Meter™ Intracellul Cell Meter™ Fluorimetri Cell Meter™ Fluorimetri Alkaline Phospatase (ALP)

Related Pathways